MDWD

+ Watchlist + Portfolio

MediWound Ltd.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $13.59
52-Week Range: $13.06 – $20.30
Market Cap: $169.32M
P/E (TTM): —
EPS (TTM): -2.09
Dividend Yield: —

Advanced Metrics

Price/Book: 4.08
PEG Ratio: —
Return on Equity: -72.37%
Return on Assets: -28.59%
Gross Margin: 15.46%
Operating Margin: -305.89%
Profit Margin: -170.10%
Current Ratio: 2.32
Debt/Equity: 0.24
Total Debt: $8.61M
Free Cash Flow: $-29.05M
Revenue Growth: -45.80%
Earnings Growth: —
Enterprise Value: $142.58M

MDWD Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$26.50M	$18.69M	$20.22M	$16.96M
Cost of Revenue	$13.33M	$15.11M	$17.59M	$13.71M
Gross Profit	$13.16M	$3.58M	$2.63M	$3.25M
Research & Development	$10.18M	$7.47M	$8.88M	$14.32M
Selling, General & Admin	$10.37M	$11.38M	$12.91M	$13.93M
Operating Expenses	$20.83M	$19.08M	$22.02M	$28.53M
Operating Income	-$7.66M	-$15.50M	-$19.38M	-$25.28M
EBITDA	-$18.25M	-$4.80M	-$27.93M	-$21.47M
Pretax Income	-$19.52M	-$6.53M	-$30.16M	-$23.71M
Income Tax	$78.00K	$185.00K	$61.00K	$169.00K
Net Income	-$19.60M	-$6.72M	-$30.22M	-$23.88M
Diluted EPS	-3.93	-0.75	-3.03	-2.10
Diluted Shares	4.99M	9.01M	9.96M	11.38M

MDWD Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$33.90M	$11.87M	$9.15M	$4.80M
Receivables	$9.70M	$4.42M	$5.85M	$2.37M
Inventory	$1.96M	$2.85M	$2.69M	$4.09M
Current Assets	$45.84M	$49.70M	$52.16M	$59.96M
Total Assets	$50.02M	$66.46M	$73.50M	$86.25M
Current Liabilities	$12.06M	$18.13M	$26.54M	$25.71M
Total Debt	$846.00K	$6.35M	$6.51M	$8.15M
Total Liabilities	$39.10M	$34.86M	$42.34M	$42.62M
Retained Earnings	-$168.11M	-$174.82M	-$205.05M	-$228.93M
Shareholders' Equity	$10.91M	$31.59M	$31.15M	$43.63M
Working Capital	$33.78M	$31.57M	$25.62M	$34.26M

MDWD Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$11.88M	-$10.46M	-$13.62M	-$16.12M
Capital Expenditure	-$555.00K	-$6.46M	-$6.27M	-$5.50M
Free Cash Flow	-$12.44M	-$16.93M	-$19.90M	-$21.63M
Depreciation & Amortisation	$1.27M	$1.30M	$1.48M	$1.86M
Stock-Based Compensation	$1.95M	$1.94M	$3.14M	$3.11M
Investing Cash Flow	-$481.00K	-$34.32M	-$8.40M	-$17.95M
Financing Cash Flow	$35.76M	$22.92M	$19.39M	$29.62M
Net Change in Cash	$23.40M	-$21.87M	-$2.63M	-$4.45M

MDWD Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$3.96M	$5.71M	$5.43M	$1.87M	$1.48M
Cost of Revenue	$3.22M	$4.37M	$4.53M	$1.59M	$1.15M
Gross Profit	$738.00K	$1.34M	$896.00K	$278.00K	$323.00K
Research & Development	$2.89M	$3.49M	$3.46M	$4.48M	$5.18M
Selling, General & Admin	$3.07M	$3.57M	$3.96M	$3.33M	$3.56M
Operating Expenses	$5.96M	$7.06M	$7.42M	$8.09M	$8.30M
Operating Income	-$5.22M	-$5.72M	-$6.53M	-$7.81M	-$7.98M
EBITDA	-$4.87M	-$5.32M	-$6.11M	-$5.17M	-$7.60M
Pretax Income	-$721.00K	-$13.28M	-$2.60M	-$7.11M	-$2.97M
Income Tax	$5.00K	$38.00K	$53.00K	$73.00K	-$17.00K
Net Income	-$726.00K	-$13.32M	-$2.65M	-$7.18M	-$2.95M
Diluted EPS	-0.07	-1.23	-0.24	-0.56	-0.23
Diluted Shares	10.80M	10.84M	11.02M	12.83M	12.87M

MDWD Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	—	—	—	$4.80M	—
Receivables	$5.18M	$6.80M	$6.04M	$2.37M	$2.75M
Inventory	$3.58M	$3.84M	$4.41M	$4.09M	$4.77M
Current Assets	$47.02M	$43.08M	$69.53M	$59.96M	$52.17M
Total Assets	$69.02M	$67.00M	$94.42M	$86.25M	$79.98M
Current Liabilities	$21.84M	$29.07M	$26.25M	$25.71M	$21.65M
Total Debt	$6.42M	$8.07M	$8.27M	$8.15M	$8.13M
Total Liabilities	$37.74M	$46.88M	$44.27M	$42.62M	$38.56M
Retained Earnings	—	—	—	-$228.93M	—
Shareholders' Equity	$31.27M	$20.12M	$50.16M	$43.63M	$41.42M
Working Capital	$25.18M	$14.01M	$43.28M	$34.26M	$30.52M

MDWD Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.11M	-$5.76M	-$3.24M	-$3.02M	-$6.75M
Capital Expenditure	-$959.00K	-$1.05M	-$1.04M	-$2.45M	-$1.82M
Free Cash Flow	-$5.07M	-$6.80M	-$4.28M	-$5.47M	-$8.57M
Depreciation & Amortisation	$358.00K	$394.00K	$418.00K	$690.00K	$378.00K
Stock-Based Compensation	$844.00K	$862.00K	$740.00K	$662.00K	$644.00K
Investing Cash Flow	-$3.34M	$4.91M	$4.38M	-$23.89M	$17.76M
Financing Cash Flow	-$362.00K	$549.00K	$30.52M	-$1.09M	-$421.00K
Net Change in Cash	-$7.82M	-$302.00K	$31.66M	-$28.00M	$10.58M

Market Snapshot

About

MediWound Ltd. is an Israeli biopharmaceutical company specializing in the development, manufacturing, and commercialization of enzymatic therapeutics for severe burns, chronic wounds, and other hard-to-heal wounds. The company markets NexoBrid for burn wound debridement and EscharEx for chronic wound treatment.